市場調査レポート

商品コード

1737055

標的タンパク質分解市場：分解装置タイプ別、適応症別、主要地域別

Targeted Protein Degradation Market Distribution by Type of Degrader, Target Indication, Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World )

出版日: 2025年05月26日
発行: Roots Analysis
ページ情報: 英文 450 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,799 691,439円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,008,415円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,527,103円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,593,295円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.08円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の標的タンパク質分解の市場規模は、2035年までの予測期間中に32%のCAGRで拡大し、現在の4億8,000万米ドルから2035年までに69億4,000万米ドルに成長すると予測されています。

この市場セグメンテーションでは、市場規模と機会分析を以下のパラメータで区分しています：

分解装置タイプ別

SERD
プロタック
分子接着剤

適応症別

乳がん
多発性骨髄腫

主要地域別

北米（米国、カナダ）
欧州（英国、ドイツ、フランス、イタリア、スペイン）
アジア太平洋（中国、韓国、日本、インド、オーストラリア）
その他の地域（ブラジル、イスラエル）

標的タンパク質分解市場：成長と動向

標的タンパク質分解（TPD）は、治療困難な疾患の治療を可能にする可能性を秘めた新たな治療手段です。低分子阻害剤やモノクローナル抗体などの従来の医薬品がプロテオームの20％未満しか標的としないのに対し、TPDはプロテオーム内の未探索タンパク質の大部分にアクセスする新しいアプローチを提供します。TPDによって、有害なタンパク質の機能を調節したり阻害したりするのではなく、その量をコントロールすることで病気に対処することができます。タンパク質量の制御は、タンパク質分解剤と呼ばれる低分子薬物によって達成されます。TPDは、E3ユビキチンリガーゼを目的のタンパク質にリクルートし、ユビキチン化とそれに続くプロテアソームによるタンパク質分解を仲介する二機能性低分子です。

Targeted Protein Degradation Market-IMG1

低分子を介した選択的TPDには、従来の創薬戦略にはない利点がいくつかあります。主な利点のひとつは、細胞機構における多層的な選択性を活用することによって、標的特異性を迅速に検証できることです。さらに、TPD分解分子が破壊されないという事実のおかげで、有害なタンパク質の多くのコピーを破壊し、全身的な薬物曝露を減らすことができます。さらに、タンパク質の機能を阻害することで、標的タンパク質の発現増加に対抗することができます。一つのタンパク質分解剤が、標的タンパク質のプロテアソーム分解を通じて、複数の病気の原因となるタンパク質を除去できる可能性があることは注目に値します。上記のような利点と現在進行中の技術進歩のペースにより、標的タンパク質分解市場は予測期間中に顕著な成長を遂げるものと思われます。

標的タンパク質分解市場：主要インサイト

当レポートでは、標的タンパク質分解市場の現状を掘り下げ、業界内の潜在的な成長機会を特定しています。当レポートの主な調査結果は以下の通りです：

285以上の標的タンパク質分解療法が承認されているか、異なる開発段階で研究されています。市場情勢は、既存参入企業と新規参入企業の両方の存在を特徴としています。
評価されている標的タンパク質分解剤の20％以上が分子接着剤であり、そのうち70％以上ががん疾患の治療を目的としています。
35％以上の技術はPROTACsの開発に焦点を当てており、このうち38％はCADD解析を利用してターゲットを同定する能力を持っています。

Targeted Protein Degradation Market-IMG2

現在、約85の革新的な標的タンパク質分解技術が、安定的で有効な分解剤の開発に利用可能です。
現在、さまざまな地域にわたり、さまざまな疾患の治療を目的とした標的タンパク質分解療法を調査するため、約250件の臨床試験（登録患者数は約63,000人）が進行中です。
2019年以降、1億6,500万米ドル以上の助成金がNIHから授与されており、これらの助成金の～80％は1～4年の支援期間で授与されました。

Targeted Protein Degradation Market-IMG3

過去5年間で、様々なインパクトのあるジャーナルに複数の論文が掲載され、このような論文はアジア太平洋地域でより多くの関心を集めています。
この分野で生み出された知的財産を保護するため、産業界および非産業界の参入企業により、標的タンパク質分解剤および関連技術に関する特許が985件以上出願されています。
関心の高まりは、最近の様々な利害関係者間で結ばれた幅広いパートナーシップにも反映されており、取引の25％は新規タンパク質分解剤の研究開発に焦点を当てたものでした。
いくつかの投資家は、標的タンパク質分解の領域における機会に気づき、過去6年間にさまざまな資金調達ラウンドで約135億米ドルを投資しました。
標的タンパク質分解市場は、治療不可能な標的を選択的に分解するタンパク質分解剤の能力により、今後10年間で年率32％の成長が見込まれています。

Targeted Protein Degradation Market-IMG4

市場推計・予測は、特に米国、フランス、スペイン、英国、中国など、さまざまな国に分散すると予測されています。

標的タンパク質分解市場：主要セグメント

分解装置タイプ別では、市場はSERD、PROTAC、分子接着剤に区分されます。現在、転移性乳がんに対する経口SERDであるエラセストラント（ORSERDU）の承認により、標的タンパク質分解市場ではSERD分野が最大シェアを占めています。さらに、PROTACセグメントは予測期間中により速いペースで成長するとみられます。

標的適応症別では、市場は乳がんと多発性骨髄腫に区分されます。現在、標的タンパク質分解市場で最も高い割合を占めているのは乳がんです。この動向は、新たに診断される症例の12.5%以上を占める乳がんの有病率の増加により、今後も変わらないと思われます。さらに、乳がんセグメントの標的タンパク質分解市場は、予測期間中に比較的高いCAGRで成長する可能性が高いです。

主要地域別に見ると、市場は北米、欧州、アジア太平洋地域、その他の地域に区分されます。現在、北米が標的タンパク質分解市場を独占しており、最大の収益シェアを占めています。さらに、アジア太平洋地域の市場は、今後数年間でより高いCAGRで成長すると予想されています。

当レポートでは、世界の標的タンパク質分解市場について調査し、市場の概要とともに、分解装置タイプ別、適応症別、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 6.1 Targeted Protein Degradation Therapies: Information on Developer, Stage of Development and Type of Degrader
Table 6.2 Targeted Protein Degradation Therapies: Information on Biological Target, Target Enzyme, Target Indication and Therapeutic Area
Table 6.3 Targeted Protein Degradation Therapy Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 7.1 Targeted Protein Degradation Technologies: Information on Type of Degrader Developed, Protein Degradation Pathway and Site of Degraded Protein
Table 7.2 Targeted Protein Degradation Technologies: Information on Therapeutic Area
Table 7.3 Targeted Protein Degradation Technologies: Information on Discovery Step Supported and CADD Ability
Table 7.4 Targeted Protein Degradation Technology Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 8.1 List of Targeted Protein Degradation Therapy Developers Profiled
Table 8.2 Arvinas: Company Overview
Table 8.3 Arvinas: Technology Portfolio
Table 8.4 Arvinas: Pipeline Overview
Table 8.5 Arvinas: Recent Developments and Future Outlook
Table 8.6 Bristol-Myers Squibb: Company Overview
Table 8.7 Bristol-Myers Squibb: Technology Portfolio
Table 8.8 Bristol-Myers Squibb: Pipeline Overview
Table 8.9 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 8.10 C4 Therapeutics: Company Overview
Table 8.11 C4 Therapeutics: Technology Portfolio
Table 8.12 C4 Therapeutics: Pipeline Overview
Table 8.13 C4 Therapeutics: Recent Developments and Future Outlook
Table 8.14 Loxo Oncology: Company Overview
Table 8.15 Loxo Oncology: Pipeline Overview
Table 8.16 Olema Oncology: Company Overview
Table 8.17 Olema Oncology: Pipeline Overview
Table 8.18 Olema Oncology: Recent Developments and Future Outlook
Table 8.19 Radius Health: Company Overview
Table 8.20 Radius Health: Pipeline Overview
Table 8.21 Radius Health: Recent Developments and Future Outlook
Table 8.22 AstraZeneca: Company Overview
Table 8.23 AstraZeneca: Pipeline Overview
Table 8.24 Roche: Company Overview
Table 8.25 Roche: Pipeline Overview
Table 8.26 BeiGene: Company Overview
Table 8.27 BeiGene: Pipeline Overview
Table 8.28 InnoCare Pharma: Company Overview
Table 8.29 InnoCare Pharma: Technology Portfolio
Table 8.30 InnoCare Pharma: Pipeline Overview
Table 8.31 Kangpu Biopharmaceuticals: Company Overview
Table 8.32 Kangpu Biopharmaceuticals: Technology Portfolio
Table 8.33 Kangpu Biopharmaceuticals: Pipeline Overview
Table 8.34 Kintor Pharmaceutical: Company Overview
Table 8.35 Kintor Pharmaceutical: Technology Portfolio
Table 8.36 Kintor Pharmaceutical: Pipeline Overview
Table 8.37 Medivir: Company Overview
Table 8.38 Medivir: Technology Portfolio
Table 8.39 Medivir: Pipeline Overview
Table 8.40 Monte Rosa Therapeutics: Company Overview
Table 8.41 Monte Rosa Therapeutics: Technology Portfolio
Table 8.42 Monte Rosa Therapeutics: Pipeline Overview
Table 8.43 Ranok Therapeutics: Company Overview
Table 8.44 Ranok Therapeutics: Technology Portfolio
Table 8.45 Ranok Therapeutics: Pipeline Overview
Table 8.46 Sanofi: Company Overview
Table 8.47 Sanofi: Pipeline Overview
Table 8.48 Zentalis Pharmaceuticals: Company Overview
Table 8.49 Zentalis Pharmaceuticals: Technology Portfolio
Table 8.50 Zentalis Pharmaceuticals: Pipeline Overview
Table 8.51 Eisai Therapeutics: Company Overview
Table 8.52 Eisai Therapeutics: Pipeline Overview
Table 11.1 Patent Analysis: Top CPC Sections
Table 11.2 Patent Analysis: Top CPC Symbols
Table 11.3 Patent Analysis: Top CPC Codes
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (By Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (By Number of Citations)
Table 13.1 Targeted Protein Degradation: List of Partnerships and Collaborations
Table 13.2 Partnerships and Collaborations: Information on Type of Agreement (Country and Region)
Table 14.1 Targeted Protein Degradation: List of Funding and Investments, Since 2018
Table 16.1 List of Targeted Protein Degradation Therapies Forecasted
Table 21.1 Targeted Protein Degradation Technologies: Average Upfront Payment and Average Milestone Payment, Since 2015 (USD Million)
Table 21.2 Library Licensing Deal: Tranches of Milestone Payments
Table 22.1 GlycoEra: Company Snapshot
Table 22.2 Polyprox Therapeutics: Company Snapshot
Table 22.3 Xios Therapeutics: Company Snapshot
Table 22.4 Mission Therapeutics: Company Snapshot
Table 22.5 Ubiquigent: Company Snapshot
Table 22.6 Almac Discovery: Company Snapshot
Table 22.7 University of Delaware: Company Snapshot
Table 22.8 Francis Crick Institute: Company Snapshot
Table 22.9 Anonymous: Company Snapshot
Table 22.10 Anonymous: Company Snapshot
Table 24.1 Targeted Protein Degradation Therapies: Distribution by Stage of Development
Table 24.2 Targeted Protein Degradation Technologies: Distribution by Type of Degrader
Table 24.3 Targeted Protein Degradation Therapies: Distribution by Biological Target
Table 24.4 Targeted Protein Degradation Therapies: Distribution by Target Enzyme
Table 24.5 Targeted Protein Degradation Therapies: Distribution by Target Indication
Table 24.6 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
Table 24.7 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment
Table 24.8 Targeted Protein Degradation Therapy Developers: Distribution by Company Size
Table 24.9 Targeted Protein Degradation Therapy Developers: Distribution by Location of Headquarters (Region)
Table 24.10 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment and Location of Headquarters (Region)
Table 24.11 Targeted Protein Degradation Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 24.12 Most Active Developers: Distribution by Number of Therapies and Stage of Development
Table 24.13 Targeted Protein Degradation Technologies: Distribution by Type of Degrader Developed
Table 24.14 Targeted Protein Degradation Technologies: Distribution by Protein Degradation Pathway
Table 24.15 Targeted Protein Degradation Technologies: Distribution by Site of Degraded Protein
Table 24.16 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
Table 24.17 Targeted Protein Degradation Therapies: Distribution by Discovery Step Supported
Table 24.18 Targeted Protein Degradation Technologies: Distribution by Availability of Computational Modeling Ability
Table 24.19 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment
Table 24.20 Targeted Protein Degradation Technology Providers: Distribution by Company Size
Table 24.21 Targeted Protein Degradation Technology Providers: Distribution by Location of Headquarters (Region)
Table 24.22 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment and Location of Headquarters (Region)
Table 24.23 Targeted Protein Degradation Technology Providers: Distribution by Company Size and Location of Headquarters (Region)
Table 24.24 Arvinas: Annual Revenues, Since FY 2019 (USD Million)
Table 24.25 Bristol-Myers Squibb: Annual Revenues, Since FY 2019 (USD Billion)
Table 24.26 C4 Therapeutics: Annual Revenues, Since FY 2019 (USD Million)
Table 24.27 Radius Health: Annual Revenues, Since FY 2019 (USD Million)
Table 24.28 AstraZeneca: Annual Revenues, Since FY 2019 (USD Billion)
Table 24.29 Roche: Annual Revenues, Since FY 2019 (CHF Billion)
Table 24.30 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2019
Table 24.31 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Since 2019
Table 24.32 Clinical Trial Analysis: Distribution by Trial Phase
Table 24.33 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Table 24.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2019
Table 24.35 Clinical Trial Analysis: Distribution by Trial Status
Table 24.36 Clinical Trial Analysis: Distribution by Patient Gender
Table 24.37 Clinical Trial Analysis: Distribution by Target Indication
Table 24.38 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 24.39 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 24.40 Clinical Trial Analysis: Distribution by Trial Purpose
Table 24.41 Clinical Trial Analysis: Distribution by Distribution by Design Allocation
Table 24.42 Leading Industry Players: Distribution by Number of Registered Trials
Table 24.43 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 24.44 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 24.45 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 24.46 Grants Analysis: Cumulative Year-wise Trend, Since 2019
Table 24.47 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
Table 24.48 Grants Analysis: Distribution by Funding Institute Center
Table 24.49 Grants Analysis: Distribution by Funding Institute Center and Support Period
Table 24.50 Grants Analysis: Distribution by Support Period
Table 24.51 Grants Analysis: Distribution by Type of Grant Application
Table 24.52 Grants Analysis: Distribution by Purpose of Grant Award
Table 24.53 Grants Analysis: Distribution by Activity Code (Series)
Table 24.54 Grants Analysis: Distribution by Activity Code
Table 24.55 Grants Analysis: Distribution by Study Section Involved
Table 24.56 Most Popular NIH Departments: Distribution by Number of Grants
Table 24.57 Prominent Program Officers: Distribution by Number of Grants
Table 24.58 Popular Recipient Organizations: Distribution by Number of Grants
Table 24.59 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Table 24.60 Popular Recipient Organizations: Distribution by States in the US
Table 24.61 Patent Analysis: Distribution by Type of Patent
Table 24.62 Patent Analysis: Distribution by Patent Publication Year, Since 2019
Table 24.63 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
Table 24.64 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2019
Table 24.65 Patent Analysis: Distribution by Patent Jurisdiction
Table 24.66 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
Table 24.67 Leading Industry Players: Distribution by Number of Patents
Table 24.68 Leading Non-Industry Players: Distribution by Number of Patents
Table 24.69 Leading Patent Assignees: Distribution by Number of Patents
Table 24.70 Patent Analysis: Distribution by Patent Age
Table 24.71 Patent Analysis: Patent Valuation
Table 24.72 Publication Analysis: Distribution by Year of Publication, Since 2019
Table 24.73 Publication Analysis: Distribution by Type of Publication
Table 24.74 Key Journals: Distribution by Number of Publications
Table 24.75 Key Journals: Distribution by Journal Impact Factor
Table 24.76 Most Active Publisher: Distribution by Number of Publications
Table 24.77 Most Active Copyright Holder: Distribution by Number of Publications
Table 24.78 Publication Analysis: Emerging Focus Area
Table 24.79 Publication Analysis: Distribution by Therapeutic Area
Table 24.80 Publication Analysis: Distribution by Geography
Table 24.81 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2016
Table 24.82 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.83 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2016
Table 24.84 Partnerships and Collaborations: Distribution by Type of Partner
Table 24.85 Partnerships and Collaborations: Distribution by Type of Degrader
Table 24.86 Most Active Players: Distribution by Number of Partnerships
Table 24.87 Partnerships and Collaborations: Local and International Agreements
Table 24.88 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 24.89 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2014
Table 24.90 Funding and Investment Analysis: Distribution by Amount Invested, Since 2014 (USD Million)
Table 24.91 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2018
Table 24.92 Funding and Investments: Distribution by Type of Funding and Amount Invested (USD Million)
Table 24.93 Year wise Distribution of Amount Invested by Type of Funding, Since 2018
Table 24.94 Funding and Investments: Distribution by Geography (Region)
Table 24.95 Funding and Investments: Distribution by Geography (Country)
Table 24.96 Most Active Players: Distribution by Number of Funding Instances
Table 24.97 Most Active Players: Distribution by Amount Raised (USD Million)
Table 24.98 Key Investors: Distribution by Number of Funding Instances
Table 24.99 Funding and Investments Summary, Since 2018 (USD Million)
Table 24.100 Global Targeted Protein Degradation Therapies Market, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 24.101 Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader
Table 24.102 Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.103 Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.104 Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.105 Targeted Protein Degradation Therapies Market: Distribution by Target Indication
Table 24.106 Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.107 Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.108 Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions (USD Million)
Table 24.109 Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.110 Targeted Protein Degradation Therapies Market in the US: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.111 Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.112 Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.113 Targeted Protein Degradation Therapies Market in the UK: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.114 Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.115 Targeted Protein Degradation Therapies Market in France: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.116 Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.117 Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.118 Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.119 Targeted Protein Degradation Therapies Market in China: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.120 Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.121 Targeted Protein Degradation Therapies Market in India: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.122 Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.123 Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.124 Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.125 Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.126 Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.127 Targeted Protein Degradation Therapies Market: RAD1901 / Elacestrant / Orserdu Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.128 Targeted Protein Degradation Therapies Market: Vepedegestrant / ARV-471 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.129 Targeted Protein Degradation Therapies Market: OP-1250 / OP-1250-301 / Palazestrant Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.130 Targeted Protein Degradation Therapies Market: LY3484356 / Imlunestrant Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.131 Targeted Protein Degradation Therapies Market: CC-92480 / BMS-986348 / Mezigdomide Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.132 Targeted Protein Degradation Therapies Market: Camizestrant / AZD9833 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.133 Global Targeted Protein Degradation Technologies Market, Historical Trends (Since 2018), Base Scenario (USD Million)
Table 24.134 Global Targeted Protein Degradation Technologies Market, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.135 Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed (USD Million)
Table 24.136 Targeted Protein Degradation Technologies Market for Upfront Payments, Historical Trends Since 2018, Base Scenario (USD Million)
Table 24.137 Targeted Protein Degradation Technologies Market for Upfront Payments, Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.138 Targeted Protein Degradation Technologies Market for Milestone Payments, Historical Trends, Since 2018, Base Scenario (USD Million)
Table 24.139 Targeted Protein Degradation Technologies Market for Milestone Payments, Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.1 Targeted Protein Degradation: List of Funding and Investments, Since 2014

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Targeted Protein Degradation Therapies Market Landscape
Figure 4.2 Executive Summary: Targeted Protein Degradation Technologies Market Landscape
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Grants Analysis
Figure 4.5 Executive Summary: Patent Analysis
Figure 4.6 Executive Summary: Publication Analysis
Figure 4.7 Executive Summary: Partnerships and Collaborations
Figure 4.8 Executive Summary: Funding and Investments
Figure 4.9 Executive Summary: Therapies Market Forecast and Opportunity Analysis
Figure 4.10 Executive Summary: Technologies Market Forecast and Opportunity Analysis
Figure 5.1 Timeline of Induced Protein Degradation Field
Figure 5.2 Ubiquitin-Proteasome System Pathway
Figure 5.3 Types of Protein Degraders
Figure 5.4 Mechanism of Action of PROTAC
Figure 5.5 Advantages of PROTACs
Figure 5.6 Mechanism of Action of ENDTAC
Figure 5.7 Mechanism of Action of PHOTAC
Figure 5.8 Mechanism of Action of Hydrophobic Tag
Figure 5.9 Mechanism of Action of IMiD
Figure 5.10 Mechanism of Action of Molecular Glue
Figure 5.11 Mechanism of Action of SERD
Figure 5.12 Mechanism of Action of SNIPER
Figure 5.13 Protein Degradation: Targeted Therapeutic Areas
Figure 6.1 Targeted Protein Degradation Therapies: Distribution by Stage of Development
Figure 6.2 Targeted Protein Degradation Technologies: Distribution by Type of Degrader
Figure 6.3 Targeted Protein Degradation Therapies: Distribution by Biological Target
Figure 6.4 Targeted Protein Degradation Therapies: Distribution by Target Enzyme
Figure 6.5 Targeted Protein Degradation Therapies: Distribution by Target Indication
Figure 6.6 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
Figure 6.7 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment
Figure 6.8 Targeted Protein Degradation Therapy Developers: Distribution by Company Size
Figure 6.9 Targeted Protein Degradation Therapy Developers: Distribution by Location of Headquarters (Region)
Figure 6.10 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment and Location of Headquarters (Region)
Figure 6.11 Targeted Protein Degradation Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 6.12 Most Active Developers: Distribution by Number of Therapies and Stage of Development
Figure 7.1 Targeted Protein Degradation Technologies: Distribution by Type of Degrader Developed
Figure 7.2 Targeted Protein Degradation Technologies: Distribution by Protein Degradation Pathway
Figure 7.3 Targeted Protein Degradation Technologies: Distribution by Site of Degraded Protein
Figure 7.4 Targeted Protein Degradation Technologies: Distribution by Therapeutic Area
Figure 7.5 Targeted Protein Degradation Technologies: Distribution by Discovery Step Supported
Figure 7.6 Targeted Protein Degradation Technologies: Distribution by Availability of Computational Modeling Ability
Figure 7.7 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment
Figure 7.8 Targeted Protein Degradation Technology Providers: Distribution by Company Size
Figure 7.9 Targeted Protein Degradation Technology Providers: Distribution by Location of Headquarters (Region)
Figure 7.10 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment and Location of Headquarters (Region)
Figure 7.11 Targeted Protein Degradation Technology Providers: Distribution by Company Size and Location of Headquarters (Region)
Figure 8.1 Arvinas: Annual Revenues, Since FY 2019 (USD Million)
Figure 8.2 Bristol-Myers Squibb: Annual Revenues, Since FY 2019 (USD Billion)
Figure 8.3 C4 Therapeutics: Annual Revenues, Since FY 2019 (USD Million)
Figure 8.4 Radius Health: Annual Revenues, Since FY 2019 (USD Million)
Figure 8.5 AstraZeneca: Annual Revenues, Since FY 2019 (USD Billion)
Figure 8.6 Roche: Annual Revenues, Since FY 2019 (CHF Billion)
Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2019
Figure 9.2 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Since 2019
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 9.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2019
Figure 9.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 9.8 Clinical Trial Analysis: Distribution by Target Indication
Figure 9.9 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 9.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 9.11 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 9.12 Clinical Trial Analysis: Distribution by Design Allocation
Figure 9.13 Leading Industry Players: Distribution by Number of Registered Trials
Figure 9.14 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 9.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 9.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 10.1 Grants Analysis: Cumulative Year-wise Trend, Since 2019
Figure 10.2 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
Figure 10.3 Grants Analysis: Distribution by Funding Institute Center
Figure 10.4 Grants Analysis: Distribution by Support Period
Figure 10.5 Grants Analysis: Distribution by Funding Institute Center and Support Period
Figure 10.6 Grants Analysis: Distribution by Type of Grant Application
Figure 10.7 Grants Analysis: Distribution by Purpose of Grant Award
Figure 10.8 Grants Analysis: Distribution by Activity Code (Series)
Figure 10.9 Grants Analysis: Distribution by Activity Code
Figure 10.10 Grants Analysis: Distribution by Study Section Involved
Figure 10.11 Most Popular NIH Departments: Distribution by Number of Grants
Figure 10.12 Prominent Program Officers: Distribution by Number of Grants
Figure 10.13 Popular Recipient Organizations: Distribution by Number of Grants
Figure 10.14 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Figure 10.15 Popular Recipient Organizations: Distribution by States in the US
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Distribution by Patent Publication Year, Since 2019
Figure 11.3 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
Figure 11.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2019
Figure 11.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 11.6 Patent Analysis: Distribution by CPC Symbols
Figure 11.7 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
Figure 11.8 Leading Industry Players: Distribution by Number of Patents
Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 11.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 11.13 Patent Analysis: Distribution by Patent Age
Figure 11.14 Targeted Protein Degradation: Patent Valuation
Figure 12.1 Publication Analysis: Distribution by Year of Publication, Since 2019
Figure 12.2 Publication Analysis: Distribution by Type of Publication
Figure 12.3 Key Journals: Distribution by Number of Publications
Figure 12.4 Key Journals: Distribution by Journal Impact Factor
Figure 12.5 Most Active Publisher: Distribution by Number of Publications
Figure 12.6 Most Active Copyright Holder: Distribution by Number of Publications
Figure 12.7 Publication Analysis: Emerging Focus Area
Figure 12.8 Publication Analysis: Distribution by Therapeutic Area
Figure 12.9 Publication Analysis: Distribution by Geography
Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2016
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2016
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 13.5 Partnerships and Collaborations: Distribution by Type of Degrader
Figure 13.6 Most Active Players: Distribution by Number of Partnerships
Figure 13.7 Partnership and Collaborations: Local and International Agreements
Figure 13.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2014
Figure 14.2 Funding and Investment Analysis: Distribution by Amount Invested, Since 2014 (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2018
Figure 14.4 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 14.5 Year-wise Distribution of Amount Invested by Type of Funding, Since 2018
Figure 14.6 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 14.7 Funding and Investment Analysis: Distribution by Geography (Country)
Figure 14.8 Most Active Players: Distribution by Number of Funding Instances
Figure 14.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 14.10 Leading Investors: Distribution by Number of Funding Instances
Figure 14.11 Funding and Investment Summary, Since 2018 (USD Million)
Figure 15.1 Targeted Protein Degradation: Market Drivers
Figure 15.2 Targeted Protein Degradation: Market Restraints
Figure 15.3 Targeted Protein Degradation: Market Opportunities
Figure 15.4 Targeted Protein Degradation: Market Challenges
Figure 16.1 Global Targeted Protein Degradation Therapies Market, Till 2035 (USD Million)
Figure 16.2 Global Targeted Protein Degradation Therapies Market, Till 2035: Conservative Scenario (USD Million)
Figure 16.3 Global Targeted Protein Degradation Therapies Market, Till 2035: Optimistic Scenario (USD Million)
Figure 17.1 Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader
Figure 17.2 Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates (Till 2035) (USD Million)
Figure 17.3 Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates (Till 2035) (USD Million)
Figure 17.4 Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates (Till 2035) (USD Million)
Figure 18.1 Targeted Protein Degradation Therapies Market: Distribution by Target Indication
Figure 18.2 Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates (Till 2035) (USD Million)
Figure 18.3 Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.1 Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions (USD Million)
Figure 19.2 Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.3 Targeted Protein Degradation Therapies Market in the US: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.4 Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.5 Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.6 Targeted Protein Degradation Therapies Market in the UK: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.7 Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.8 Targeted Protein Degradation Therapies Market in France: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.9 Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.10 Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.11 Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.12 Targeted Protein Degradation Therapies Market in China: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.13 Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.14 Targeted Protein Degradation Therapies Market in India: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.15 Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.16 Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.17 Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.18 Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.19 Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates (Till 2035) (USD Million)
Figure 20.1 Targeted Protein Degradation Therapies Market: RAD1901 / Elacestrant / Orserdu Sales Forecast, Till 2035 (USD Million)
Figure 20.2 Targeted Protein Degradation Therapies Market: Vepedegestrant / ARV-471 Sales Forecast, Till 2035 (USD Million)
Figure 20.3 Targeted Protein Degradation Therapies Market: OP-1250 / OP-1250-301 / Palazestrant Sales Forecast, Till 2035 (USD Million)
Figure 20.4 Targeted Protein Degradation Therapies Market: LY3484356 / Imlunestrant Sales Forecast, Till 2035 (USD Million)
Figure 20.5 Targeted Protein Degradation Therapies Market: CC-92480 / BMS-986348 / Mezigdomide Sales Forecast, Till 2035 (USD Million)
Figure 20.6 Targeted Protein Degradation Therapies Market: Camizestrant / AZD9833 Sales Forecast, Till 2035 (USD Million)
Figure 21.1 Licensing Agreements: Distribution of Financial Components
Figure 21.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 21.3 Global Targeted Protein Degradation Technologies Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.4 Global Targeted Protein Degradation Technologies Market, Till 2035: Conservative Scenario (USD Million)
Figure 21.5 Global Targeted Protein Degradation Technologies Market, Till 2035: Optimistic Scenario (USD Million)
Figure 21.6 Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed
Figure 21.7 Targeted Protein Degradation Technologies Market for Upfront Payments, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.8 Targeted Protein Degradation Technologies Market for Milestone Payments, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.1 Conclusion: Targeted Protein Degradation Therapies Market Landscape
Figure 23.2 Conclusion: Targeted Protein Degradation Technologies Market Landscape
Figure 23.3 Conclusion: Clinical Trial Analysis
Figure 23.4 Conclusion: Grants Analysis
Figure 23.5 Conclusion: Patent Analysis
Figure 23.6 Conclusion: Publication Analysis
Figure 23.7 Conclusion: Partnerships and Collaborations
Figure 23.8 Conclusion: Funding and Investments
Figure 23.9 Conclusion: Therapies Market Forecast and Opportunity Analysis
Figure 23.10 Conclusion: Technologies Market Forecast and Opportunity Analysis

Product Code: RA100259A

TARGETED PROTEIN DEGRADATION MARKET: OVERVIEW

As per Roots Analysis, the global targeted protein degradation market is estimated to grow from USD 0.48 billion in the current year to USD 6.94 billion by 2035, at a CAGR of 32% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Degrader

SERD
PROTAC
Molecular Glue

Target Indication

Breast Cancer
Multiple Myeloma

Key Geographical Regions

North America (US and Canada)
Europe (UK, Germany, France, Italy and Spain)
Asia-Pacific (China, South Korea, Japan, India and Australia)
Rest of the World (Brazil and Israel)

TARGETED PROTEIN DEGRADATION MARKET: GROWTH AND TRENDS

Targeted protein degradation (TPD) is an emerging therapeutic modality that has the potential to enable the treatment of difficult-to-treat diseases. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, target less than 20% of the proteome, TPD provides a novel approach to access the vast majority of unexplored proteins within the proteome. Through TPD, a disease can be addressed by controlling the amount of harmful protein rather than trying to modulate or inhibit its function. The control of protein levels is accomplished with a small molecule drug, called a protein degrader. TPD is a bifunctional small molecule that recruits E3 ubiquitin ligases to the protein of interest and mediates its ubiquitination and subsequent proteolysis by the proteasome.

Small molecule-mediated selective TPD has several advantages over traditional drug discovery strategies. One of the primary advantages is the high degree of target specificity that can be rapidly validated by leveraging the multiple layers of selectivity in the cellular machinery. Moreover, owing to the fact that the TPD degrader molecules cannot be destroyed, they can cause the destruction of many copies of harmful proteins and reduce systemic drug exposure. In addition, it can counteract increased target protein expression by inhibiting the protein function. It is worth noting that a single protein degrader has the ability to potentially eliminate multiple disease-causing proteins through proteasome degradation of the target protein. Owing to the above-mentioned advantages and the ongoing pace of technological advancements, the targeted protein degradation market is poised to experience noteworthy growth during the forecast period.

TARGETED PROTEIN DEGRADATION MARKET: KEY INSIGHTS

The report delves into the current state of the targeted protein degradation market and identifies potential growth opportunities within industry. Some key findings from the report include:

285+ targeted protein degradation therapies are either approved or being investigated in different stages of development; the market landscape features the presence of both established players and new entrants.
Over 20% of the targeted protein degraders being evaluated are molecular glues; of these, more than 70% are intended for the treatment of oncological disorders.
Over 35% of the technologies are focused on developing PROTACs; of these, 38% have the capability to identify the targets utilizing CADD analysis.

At present, around 85 innovative targeted protein degradation technologies are available for developing stable and efficacious degraders; further, majority of the technology providers are start-ups / small businesses.
Around 250 clinical trials (with around 63,000 enrolled patients) are currently underway to investigate targeted protein degradation therapies intended for treatment of various diseases, across different geographies.
Since 2019, grants worth over USD 165 million have been awarded by NIH; ~80% of these grants were awarded for a support period of 1-4 years.

In the last five years, several articles have been published in various high-impact journals; such publications have garnered more interest in the Asia-Pacific region.
More than 985 patents have been filed for targeted protein degraders and related technologies by industry and non-industry players, to protect intellectual property generated within this field.
The rising interest is reflected in the wide array of partnerships established between various stakeholders in the recent past; 25% of the deals were focused on research and development of novel protein degraders.
Several investors have realized the opportunity within the domain of targeted protein degradation and invested around USD 13.5 billion across various funding rounds in the past six years.
Owing to the protein degraders ability to degrade the undruggable targets selectively, the targeted protein degradation therapies market is anticipated to witness an annualized growth of 32% over the next decade.

The estimated market opportunity is projected to be distributed across different countries, especially in the US, France, Spain, the UK and China.

TARGETED PROTEIN DEGRADATION MARKET: KEY SEGMENTS

SERD Segment Occupies the Largest Share of the Targeted Protein Degradation Market

Based on the type of degrader, the market is segmented into SERD, PROTAC and molecular glue. At present, the SERD segment holds the maximum share of the targeted protein degradation market owing to the approval of elacestrant (ORSERDU), an oral SERD for metastatic breast cancer. Additionally, the PROTAC segment is likely to grow at a faster pace during the forecasted period.

By Target Indication, Breast Cancer is the Fastest Growing Segment of the Global Targeted Protein Degradation Market

Based on the target indication, the market is segmented into breast cancer and multiple myeloma. Currently, the breast cancer segment captures the highest proportion of the targeted protein degradation market. This trend is likely to remain the same in the future owing to the increasing prevalence of breast cancer, with over 12.5% of all newly diagnosed cases. Further, targeted protein degradation market for the breast cancer segment is likely to grow at a relatively higher CAGR during the forecast period.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Currently, North America dominates the targeted protein degradation market and accounts for the largest revenue share. Further, the market in Asia-Pacific is expected to grow at a higher CAGR in the coming years.

Example Players in the Targeted Protein Degradation Market

Arvinas
AstraZeneca
BeiGene
Bristol-Myers Squibb
C4 Therapeutics
Eisai Therapeutics
InnoCare Pharma
Kangpu Biopharmaceuticals
Kintor Pharmaceutical
Loxo Oncology
Medivir
Monte Rosa Therapeutics
Olema Oncology
Radius Health
Ranok Therapeutics
Roche
Sanofi
Zentalis Pharmaceuticals

TARGETED PROTEIN DEGRADATION MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the targeted protein degradation market, focusing on key market segments, including [A] type of degrader, [B] target indication, and [C] key geographical regions.
Targeted Protein Degradation Therapies Market Landscape: A comprehensive evaluation of the companies engaged in targeted protein degradation therapies market, based on several relevant parameters, such as [A] stage of development, [B] type of degrader, [C] biological target, [D] target enzyme, [E] target indication and [F] therapeutic area. Additionally, a comprehensive evaluation of the targeted protein degradation therapy developers, based on several relevant parameters, such as [G] year of establishment, [H] company size, [I] location of headquarters and [J] most active players.
Targeted Protein Degradation Technologies Market Landscape: A comprehensive evaluation of the companies engaged in targeted protein degradation technologies market, based on several relevant parameters, such as [A] type of degrader developed, [B] protein degradation pathway, [C] site of degraded protein, [D] therapeutic area, [E] discovery step supported and [F] availability of computational modeling ability. Additionally, a comprehensive evaluation of the companies offering targeted protein degradation technologies, based on several relevant parameters, such as [G] year of establishment, [H] company size and [I] location of headquarters.
Company Profiles: In-depth profiles of key companies engaged in the targeted protein degradation market, focusing on [A] overview of the company, [B] financial information (if available), [C] technology portfolio, [D] pipeline overview and [E] recent developments and an [F] informed future outlook.
Clinical Trial Analysis: An insightful analysis of clinical trials related to targeted protein degradation, based on several parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] trial phase, [D] trial status, [E] patient gender, [F] target indication, [G] study design, [H] most active sponsor / collaborator and [I] geography.
Grants Analysis: A comprehensive assessment of grants that have been awarded to research institutes in the targeted protein degradation domain, based on various relevant parameters, such as [A] year of grant award, [B] amount awarded, [C] funding institute centers, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code, [H] study section involved, [I] popular NIH departments, [J] prominent program officers, [k] popular recipient organizations and [L] distribution of popular recipient organizations by states in the US.
Patent Analysis: An in-depth analysis of patents filed / granted till date in the targeted protein degradation domain, based on various relevant parameters, such as [A] type of patent, [B] patent application year, [C] patent publication year, [D] patent jurisdiction, [E] CPC symbols, [F] type of applicant, [G] individual patent assignees, [H] patent age, [I] patent benchmarking, and [J] patent valuation analysis.
Publication Analysis: An insightful analysis of peer-reviewed scientific articles related to research on targeted protein degradation, based on various relevant parameters, such as [A] year of publication, [B] type of publication, [C] key journal, [D] most active publisher, [E] most active copyright holder, [F] most popular keywords, [G] therapeutic area and [H] key geographical regions.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the targeted protein degradation market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, [D] type of degrader, [E] most active players and [F] geographical distribution of the partnership activity.
Funding and Investments: An in-depth analysis of the fundings raised by targeted protein degradation companies, based on relevant parameters, such as [A] year-wise trend of funding instances, [B] amount invested, [C] type of funding, [D] geographical analysis, [E] leading players and [F] leading investors.
Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Market Overview

1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Future Estimates
- 3.2.2. Currency Coverage and Foreign Exchange Rate
  - 3.2.2.1. Major Currencies Affecting the Market
  - 3.2.2.2. Factors affecting Currency Fluctuations and Foreign Exchange Rates
  - 3.2.2.3. Impact of Foreign Exchange Rate Volatility on Market
  - 3.2.2.4. Strategies For Mitigating Foreign Exchange Risk
- 3.2.3. Trade Policies
  - 3.2.3.1. Impact of Trade Barriers on the Market
  - 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Overview of Targeted Protein Degradation
- 5.2.1. Historical Evolution of Targeted Protein Degraders
5.3. Targeted Protein Degrader Pathway
5.4. Types of Protein Degraders
- 5.4.1. Proteolysis Targeting Chimeras (PROTACs)
- 5.4.2. Endosome Targeting Chimeras (ENDTACs)
- 5.4.3. Photochemically Targeted Chimeras (PHOTACs)
- 5.4.4. Hydrophobic Tags
- 5.4.5. Immunomodulatory Imide Drugs (IMiDs)
- 5.4.6. Molecular Glues
- 5.4.7. Selective Hormone Receptor Degraders (SHRDs)
- 5.4.8. Specific and Nongenetic inhibitor-of-apoptosis proteins (IAP)- Dependent Protein Erasers (SNIPERs)
- 5.4.9. DUB Inhibitors
- 5.4.10. Other Protein Degraders
5.5. Targeted Therapeutic Areas
5.6. Benefits and Challenges Associated with Targeted Protein Degradation
5.7. Future Perspectives

6. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION THERAPIES

6.1. Chapter Overview
6.2. Targeted Protein Degradation Therapies: Overall Market Landscape
- 6.2.1. Analysis by Stage of Development
- 6.2.2. Analysis by Type of Degrader
- 6.2.3. Analysis by Biological Target
- 6.2.4. Analysis by Target Enzyme
- 6.2.5. Analysis by Target Indication
- 6.2.6. Analysis by Therapeutic Area
6.3. Targeted Protein Degradation Therapy Developers: Overall Market Landscape
- 6.3.1. Analysis by Year of Establishment
- 6.3.2. Analysis by Company Size
- 6.3.3. Analysis by Location of Headquarters (Region)
- 6.3.4. Analysis by Year of Establishment and Location of Headquarters (Region)
- 6.3.5. Analysis by Company Size and Location of Headquarters (Region)
- 6.3.6. Most Active Developers: Distribution by Number of Therapies and Stage of Development

7. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION TECHNOLOGIES

7.1. Chapter Overview
7.2. Targeted Protein Degradation Technologies: Overall Market Landscape
- 7.2.1. Analysis by Type of Degrader Developed
- 7.2.2. Analysis by Protein Degradation Pathway
- 7.2.3. Analysis by Site of Degraded Protein
- 7.2.4. Analysis by Therapeutic Area
- 7.2.5. Analysis by Discovery Step Supported
- 7.2.6. Analysis by Availability of Computational Modeling Ability
- 7.2.7. Analysis by Year of Establishment
- 7.2.8. Analysis by Company Size
- 7.2.9. Analysis by Location of Headquarters (Region)
- 7.2.10. Analysis by Year of Establishment and Location of Headquarters (Region)
- 7.2.11. Analysis by Company Size and Location of Headquarters (Region)

8. COMPANY PROFILES

8.1. Chapter Overview
8.2. Detailed Company Profiles of Prominent Players
- 8.2.1. Arvinas
  - 8.2.1.1. Company Overview
  - 8.2.1.2. Financial Information
  - 8.2.1.3. Technology Portfolio
  - 8.2.1.4. Pipeline Overview
  - 8.2.1.5. Recent Developments and Future Outlook
- 8.2.2. Bristol-Myers Squibb
  - 8.2.2.1. Company Overview
  - 8.2.2.2. Financial Information
  - 8.2.2.3. Technology Portfolio
  - 8.2.2.4. Pipeline Overview
  - 8.2.2.5. Recent Developments and Future Outlook
- 8.2.3. C4 Therapeutics
  - 8.2.3.1. Company Overview
  - 8.2.3.2. Financial Information
  - 8.2.3.3. Technology Portfolio
  - 8.2.3.4. Pipeline Overview
  - 8.2.3.5. Recent Developments and Future Outlook
- 8.2.4. Loxo Oncology
  - 8.2.4.1. Company Overview
  - 8.2.4.2. Pipeline Overview
  - 8.2.4.3. Recent Developments and Future Outlook
- 8.2.5. Olema Oncology
  - 8.2.5.1. Company Overview
  - 8.2.5.2. Pipeline Overview
  - 8.2.5.3. Recent Developments and Future Outlook
- 8.2.6. Radius Health
  - 8.2.6.1. Company Overview
  - 8.2.6.2. Financial Information
  - 8.2.6.3. Pipeline Overview
  - 8.2.6.4. Recent Developments and Future Outlook
- 8.2.7. AstraZeneca
  - 8.2.7.1. Company Overview
  - 8.2.7.2. Financial Information
  - 8.2.7.3. Pipeline Overview
  - 8.2.7.4. Recent Developments and Future Outlook
- 8.2.8. Roche
  - 8.2.8.1. Company Overview
  - 8.2.8.2. Financial Information
  - 8.2.8.3. Pipeline Overview
  - 8.2.8.4. Recent Developments and Future Outlook
8.3. Short Profiles of Other Prominent Players
- 8.3.1. BeiGene
  - 8.3.1.1. Company Overview
  - 8.3.1.2. Pipeline Overview
- 8.3.2. InnoCare Pharma
  - 8.3.2.1. Company Overview
  - 8.3.2.2. Technology Portfolio
  - 8.3.2.3. Pipeline Overview
- 8.3.3. Kangpu Biopharmaceuticals
  - 8.3.3.1. Company Overview
  - 8.3.3.2. Technology Portfolio
  - 8.3.3.3. Pipeline Overview
- 8.3.4. Kintor Pharmaceuticals
  - 8.3.4.1. Company Overview
  - 8.3.4.2. Technology Portfolio
  - 8.3.4.3. Pipeline Overview
- 8.3.5. Medivir
  - 8.3.5.1. Company Overview
  - 8.3.5.2. Technology Portfolio
  - 8.3.5.3. Pipeline Overview
- 8.3.6. Monte Rosa Therapeutics
  - 8.3.6.1. Company Overview
  - 8.3.6.2. Technology Portfolio
  - 8.3.6.3. Pipeline Overview
- 8.3.7. Ranok Therapeutics
  - 8.3.7.1. Company Overview
  - 8.3.7.2. Technology Portfolio
  - 8.3.7.3. Pipeline Overview
- 8.3.8. Sanofi
  - 8.3.8.1. Company Overview
  - 8.3.8.2. Pipeline Overview
- 8.3.9. Zentalis Pharmaceuticals
  - 8.3.9.1. Company Overview
  - 8.3.9.2. Technology Portfolio
  - 8.3.9.3. Pipeline Overview
- 8.3.10. Eisai Therapeutics
  - 8.3.10.1. Company Overview
  - 8.3.10.2. Pipeline Overview

9. CLINICAL TRIAL ANALYSIS

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Targeted Protein Degradation: Clinical Trial Analysis
- 9.3.1. Analysis by Trial Registration Year
- 9.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
- 9.3.3. Analysis by Trial Phase
- 9.3.4. Analysis of Number of Patients Enrolled by Trial Phase
- 9.3.5. Analysis by Trial Registration Year and Trial Phase
- 9.3.6. Analysis by Trial Status
- 9.3.7. Analysis by Patient Gender
- 9.3.8. Analysis by Target Indication
- 9.3.9. Analysis by Study Design
  - 9.3.9.1. Analysis by Type of Trial Masking
  - 9.3.9.2. Analysis by Type of Intervention Model
  - 9.3.9.3. Analysis by Trial Purpose
  - 9.3.9.4. Analysis by Design Allocation
- 9.3.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
  - 9.3.10.1. Analysis by Leading Industry Players
  - 9.3.10.2. Analysis by Leading Non-Industry Players
- 9.3.11. Analysis by Geography
  - 9.3.11.1. Analysis of Clinical Trials by Trial Status and Geography
  - 9.3.11.2. Analysis of Patients Enrolled by Trial Status and Geography

10. GRANTS ANALYSIS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Targeted Protein Degradation: Grants Analysis
- 10.3.1. Analysis by Year of Grant Award
- 10.3.2. Analysis by Amount Awarded
- 10.3.3. Analysis by Funding Institute Center
- 10.3.4. Analysis by Support Period
- 10.3.5. Analysis by Funding Institute Center and Support Period
- 10.3.6. Analysis by Type of Grant Application
- 10.3.7. Analysis by Purpose of Grant Award
- 10.3.8. Analysis by Activity Code
- 10.3.9. Analysis by Study Section Involved
- 10.3.10. Most Popular NIH Departments: Analysis by Number of Grants
- 10.3.11. Prominent Program Officers: Analysis by Number of Grants
- 10.3.12. Popular Recipient Organizations: Analysis by Number of Grants
- 10.3.13. Popular Recipient Organizations: Analysis by Grant Amount
- 10.3.14. Popular Recipient Organizations: Analysis by States in the US

11. PATENT ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Targeted Protein Degradation: Patents Analysis
- 11.3.1. Analysis by Patent Publication Year
- 11.3.2. Analysis by Patent Application Year
- 11.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
- 11.3.4. Analysis by Patent Jurisdiction
- 11.3.5. Analysis by CPC Symbols
- 11.3.6. Analysis by Type of Applicant
- 11.3.7. Leading Industry Players: Analysis by Number of Patents
- 11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
- 11.3.9. Leading Patent Assignees: Analysis by Number of Patents
11.4. Patent Benchmarking Analysis
- 11.4.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
11.5. Patent Valuation
11.6. Leading Patents by Number of Citations

12. PUBLICATION ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Targeted Protein Degradation: Publication Analysis
- 12.3.1. Analysis by Year of Publication
- 12.3.2. Analysis by Type of Publication
- 12.3.3. Key Journals: Analysis by Number of Publications
- 12.3.4. Key Journals: Analysis by Journal Impact Factor
- 12.3.5. Most Active Publisher: Analysis by Number of Publications
- 12.3.6. Most Active Copyright Holder: Analysis by Number of Publications
- 12.3.7. Analysis by Emerging Focus Area
- 12.3.8. Analysis by Therapeutic Area
- 12.3.9. Analysis by Geography

13. PARTNERSHIPS AND COLLABORATIONS

13.1. Chapter Overview
13.2. Partnership Models
13.3. Targeted Protein Degradation: Partnerships and Collaborations
- 13.3.1. Analysis by Year of Partnership
- 13.3.2. Analysis by Type of Partnership
- 13.3.3. Analysis by Year and Type of Partnership
- 13.3.4. Analysis by Type of Partner
- 13.3.5. Analysis by Type of Degrader
- 13.3.6. Most Active Players: Analysis by Number of Partnerships
13.4. Analysis by Geography
- 13.4.1. Local and International Agreements
- 13.4.2. Intercontinental and Intracontinental Agreements

14. FUNDING AND INVESTMENTS

14.1. Chapter Overview
14.2. Funding Models
14.3. Targeted Protein Degradation: Funding and Investments
- 14.3.1. Analysis by Year of Funding
- 14.3.2. Analysis by Amount Invested
- 14.3.3. Analysis by Type of Funding
- 14.3.4. Analysis by Amount Invested and Type of Funding
- 14.3.5. Analysis of Amount Invested by Year and Type of Funding
- 14.3.6. Analysis by Geography
- 14.3.7. Most Active Players
  - 14.3.7.1. Analysis by Number of Funding Instances
  - 14.3.7.2. Analysis by Amount Invested
- 14.3.8. Leading Investors: Analysis by Number of Funding Instances
14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion

16. GLOBAL TARGETED PROTEIN DEGRADATION THERAPIES MARKET

16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Global Targeted Protein Degradation Therapies Market, Forecasted Estimates (Till 2035)
- 16.3.1. Scenario Analysis
  - 16.3.1.1. Conservative Scenario
  - 16.3.1.2. Optimistic Scenario
16.4. Key Market Segmentations

17. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TYPE OF DEGRADER

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader
- 17.3.1. Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates (Till 2035)
- 17.3.2. Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates (Till 2035)
- 17.3.3. Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation

18. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TARGET INDICATION

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Targeted Protein Degradation Therapies Market: Distribution by Target Indication
- 18.3.1. Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates (Till 2035)
- 18.3.2. Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation

19. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions
- 19.3.1. Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates (Till 2035)
  - 19.3.1.1. Targeted Protein Degradation Therapies Market in US: Forecasted Estimates (Till 2035)
  - 19.3.1.2. Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates (Till 2035)
- 19.3.2. Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates (Till 2035)
  - 19.3.2.1. Targeted Protein Degradation Therapies Market in UK: Forecasted Estimates (Till 2035)
  - 19.3.2.2. Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates (Till 2035)
  - 19.3.2.3. Targeted Protein Degradation Therapies Market in France: Forecasted Estimates (Till 2035)
  - 19.3.2.4. Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates (Till 2035)
  - 19.3.2.5. Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates (Till 2035)
- 19.3.3. Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates (Till 2035)
  - 19.3.3.1. Targeted Protein Degradation Therapies Market in China: Forecasted Estimates (Till 2035)
  - 19.3.3.2. Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates (Till 2035)
  - 19.3.3.3. Targeted Protein Degradation Therapies Market in India: Forecasted Estimates (Till 2035)
  - 19.3.3.4. Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates (Till 2035)
  - 19.3.3.5. Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates (Till 2035)
- 19.3.4. Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates (Till 2035)
  - 19.3.4.1. Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates (Till 2035)
  - 19.3.4.2. Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates (Till 2035)
19.5. Data Triangulation and Validation

20. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, SALES FORECAST OF DRUGS

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Commercialized Targeted Protein Degradation Therapies Market: Sales Forecast
- 20.3.1. RAD1901 / Elacestrant / Orserdu Sales Forecast
20.4. Phase III Targeted Protein Degradation Therapies Market: Sales Forecast
- 20.4.1. Vepdegestrant / ARV-471 Sales Forecast
- 20.4.2. Camizestrant / AZD9833 Sales Forecast
- 20.4.3. CC-92480 / BMS-986348 / Mezigdomide Sales Forecast
- 20.4.4. LY3484356 / Imlunestrant Sales Forecast
- 20.4.5. OP-1250 / OP-1250-301 / Palazestrant Sales Forecast
20.5. Data Triangulation and Validation

21. GLOBAL TARGETED PROTEIN DEGRADATION TECHNOLOGIES MARKET

21.1. Chapter Overview
21.2. Key Assumptions
21.3. Forecast Methodology
21.4. Global Targeted Protein Degradation Technologies Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 21.4.1. Scenario Analysis
  - 21.4.1.1. Conservative Scenario
  - 21.4.1.2. Optimistic Scenario
21.5. Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed
- 21.5.1. Targeted Protein Degradation Technologies Market for Upfront Payments: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 21.5.2. Targeted Protein Degradation Technologies Market for Milestone Payments: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
21.6. Data Triangulation and Validation

22. EXECUTIVE INSIGHTS

22.1. Chapter Overview
22.2. GlycoEra
- 22.2.1. Company Snapshot
- 22.2.2. Interview Transcript: Ganesh Kaundinya, Chief Executive Officer and President
22.3. Polyprox Therapeutics
- 22.3.1. Company Snapshot
- 22.3.2. Interview Transcript: Laura Itzhaki, Chief Scientific Officer and Founder
22.4. Xios Therapeutics
- 22.4.1. Company Snapshot
- 22.4.2. Interview Transcript: Louise Bergeron, Former Chief Scientific Officer and Former Vice President, Research
22.5. Mission Therapeutics
- 22.5.1. Company Snapshot
- 22.5.2. Interview Transcript: Paul Wallace, Former Chief Business Officer
22.6. Ubiquigent
- 22.6.1. Company Snapshot
- 22.6.2. Interview Transcript: Jason Brown, Former Scientific and Business Development Director
22.7. Almac Discovery
- 22.7.1. Company Snapshot
- 22.7.2. Interview Transcript: Martin Wales, Former Vice President, Business Development and Licensing and Gerald Gavory, Former Vice President, Biology
22.8. University of Delaware
- 22.8.1. Company Snapshot
- 22.8.2. Interview Transcript: Zhihao Zhuang (Professor)
22.9 Francis Crick Institute
- 22.9.1. Company Snapshot
- 22.9.2. Interview Transcript: Katrin Rittinger (Group Leader)
22.10 Anonymous
- 22.10.1. Interview Transcript: Chief Scientific Officer
22.11 Anonymous
- 22.11.1. Interview Transcript: Director of Oncology Research

標的タンパク質分解市場：分解装置タイプ別、適応症別、主要地域別

Targeted Protein Degradation Market Distribution by Type of Degrader, Target Indication, Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World )

標的タンパク質分解市場：成長と動向

標的タンパク質分解市場：主要インサイト

標的タンパク質分解市場：主要セグメント

目次

第1章 序文

第1章 1.市場概要

第2章 調査手法

第3章 経済的およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

第6章 市場情勢：標的タンパク質分解療法

第7章 市場情勢：標的タンパク質分解技術

第8章 企業プロファイル

第9章 臨床試験の分析

第10章 助成金分析

第11章 特許分析

第12章 出版物の分析

第13章 パートナーシップとコラボレーション

第14章 資金調達と投資

第15章 市場影響分析：促進要因、抑制要因、機会、課題

第16章 世界の標的タンパク質分解市場

第17章 標的タンパク質分解市場（分解装置タイプ別）

第18章 標的タンパク質分解市場（標的適応症別）

第19章 標的タンパク質分解市場（主要地域別）

第20章 標的タンパク質分解市場、医薬品の売上予測

第21章 世界の標的タンパク質分解技術市場

第22章 エグゼクティブ洞察

第23章 結論

第24章 付録1：表形式データ

第25章 付録2：企業・団体一覧

第26章 付録3：資金調達と投資のリスト

List of Tables

List of Figures

TARGETED PROTEIN DEGRADATION MARKET: OVERVIEW

TARGETED PROTEIN DEGRADATION MARKET: GROWTH AND TRENDS

TARGETED PROTEIN DEGRADATION MARKET: KEY INSIGHTS

TARGETED PROTEIN DEGRADATION MARKET: KEY SEGMENTS

Example Players in the Targeted Protein Degradation Market

TARGETED PROTEIN DEGRADATION MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

1.1. Market Overview

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION THERAPIES

7. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION TECHNOLOGIES

8. COMPANY PROFILES

9. CLINICAL TRIAL ANALYSIS

10. GRANTS ANALYSIS

11. PATENT ANALYSIS

12. PUBLICATION ANALYSIS

13. PARTNERSHIPS AND COLLABORATIONS

14. FUNDING AND INVESTMENTS

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

16. GLOBAL TARGETED PROTEIN DEGRADATION THERAPIES MARKET

17. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TYPE OF DEGRADER

18. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TARGET INDICATION

19. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS

20. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, SALES FORECAST OF DRUGS

21. GLOBAL TARGETED PROTEIN DEGRADATION TECHNOLOGIES MARKET

22. EXECUTIVE INSIGHTS

23. CONCLUSION

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

26. APPENDIX 3: LIST OF FUNDING AND INVESTMENTS

第1章序文

第2章調査手法

第3章経済的およびその他のプロジェクト特有の考慮事項

第4章エグゼクティブサマリー

第5章イントロダクション

第6章市場情勢：標的タンパク質分解療法

第7章市場情勢：標的タンパク質分解技術

第8章企業プロファイル

第9章臨床試験の分析

第10章助成金分析

第11章特許分析

第12章出版物の分析

第13章パートナーシップとコラボレーション

第14章資金調達と投資

第15章市場影響分析：促進要因、抑制要因、機会、課題

第16章世界の標的タンパク質分解市場

第17章標的タンパク質分解市場（分解装置タイプ別）

第18章標的タンパク質分解市場（標的適応症別）

第19章標的タンパク質分解市場（主要地域別）

第20章標的タンパク質分解市場、医薬品の売上予測

第21章世界の標的タンパク質分解技術市場

第22章エグゼクティブ洞察

第23章結論

第24章付録1：表形式データ

第25章付録2：企業・団体一覧

第26章付録3：資金調達と投資のリスト